Date: Thursday, June 23, 2016
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: To evaluate the possible effect of combined intake of levodopa/carbidopa and trimethoprim/sulfamethoxazole on the duration of ON/OFF periods in a PD patient.
Background: Drug interactions, MEDLINE, PubMED was searched. No data, indicating any possible interaction between levodopa/carbidopa and trimethoprim/sulfamethoxazole was found. A PD patient with positive family history for PD was prescribed biseptol (trimethoprim/sulfamethoxazole) 480 mg/d for 10 days because of acute bronchitis. During the period of biseptol intake patient noticed a significant increase in duration of ON periods from 1.5 h up to 2.0-2.5 h. After biseptol discontinuation duration of ON periods returned to 1.5 h.
Methods: A 12 weeks-long drug challenge trial was started with the aim to establish the efficacy of biseptol in increasing the duration of Levodopa ON. Treatment schedule consisted of three 2 week periods of combined settled-dose antiParkinsonian treatment with biseptol 480 mg/d BID with alternating three 2 week periods of the same antiParkinsonian drug regimen without biseptol. Patient completed Hauser ON/OFF diary.
Results: During the three combined treatment periods a statistically significant increase by 35 min (p<0.01) per ON period was observed. The total stay in ON period per day increased by 105 min (p<0.01). During the first period results were not statistically significant (p<0.25), during the second and third combined treatment periods the increase in ON period duration was statistically significant, p 0.003 and p 0.0005
|Time||Three cycles with biseptol||Three cycles without biseptol|
|On-state, min||Off-state, min||On-state, min||Off-state, min|
|Median per day, min||460,36||522,86||355,36||624,79|
|Median per intake , min||153,45||174,29||118,45||207,26|
Conclusions: Pharmacokinetic and pharmacodynamic interactions between levodopa/carbidopa and trimethoprim/sulfamethoxazole should be checked in the population of sporadic PD patients as well as in the group of genetic variants (mendelian AD type of inheritance) of PD.
To cite this abstract in AMA style:K. Karpinska, V. Smolanka. Biseptol a new antiParkinsonian agent? [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/biseptol-a-new-antiparkinsonian-agent/. Accessed December 7, 2023.
« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/biseptol-a-new-antiparkinsonian-agent/